Brief: Marker Therapeutics Announces FDA Clearance Of IND For MT-601 For Treatment Of Relapsed/Refractory Non-Hodgkin Lymphoma
04/08/2022 22:51
Aug 4 (Reuters) - Marker Therapeutics Inc MRKR.O :
* MARKER THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND FOR
MT-601,
THE SIX-ANTIGEN TARGETED T CELL THERAPY FOR THE TREATMENT OF
RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA
* MARKER THERAPEUTICS INC - LOOKS FORWARD TO INITIATING
COMPANY-SPONSORED PHASE 1 STUDY NEXT YEAR FOR MT-601
Source text for Eikon: ID:nGNX5Jz3X3
Further company coverage: MRKR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Marker Therapeutics
See all newsBrief: Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant To Advance MT-601 In Pancreatic Cancer
Marker Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Marker Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
Marker Therapeutics 2025 net loss widens, hurt by decline in grant income
Brief: Marker Therapeutics FY Basic EPS USD -0.79